Revance Therapeu Stock Price, News & Analysis

Revance Therapeutics, Inc. (NASDAQ: RVNC) is set to release its Q2 2022 financial results on August 9, 2022, after market close. A conference call and live webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. Revance specializes in innovative aesthetic and therapeutic solutions, including its leading product, DaxibotulinumtoxinA for injection, which is under U.S. regulatory review after successful Phase 3 trials. The company also holds exclusive distribution rights for the RHA® Collection of dermal fillers.

Revance Therapeutics (RVNC) announced new data on RTP004, enhancing membrane binding of BoNT/A, during a podium presentation at the TOXINS International Conference. The ASPEN-1 Phase 3 trial results for DaxibotulinumtoxinA for cervical dystonia were presented by Dr. Cynthia Comella. The company emphasizes its commitment to neurotoxin research and the therapeutic pipeline's potential. Revance is advancing its long-acting neuromodulator, currently under U.S. regulatory review, while targeting aesthetic and therapeutic markets.

Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9 in Chicago. CEO Mark Foley is set to present on June 6 at 2:00 p.m. CT. Interested parties can access the live audio webcast on the company’s website, with a replay available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic products, including the long-acting neuromodulator DaxibotulinumtoxinA for Injection, currently pursuing U.S. regulatory approval for use in glabellar lines and cervical dystonia.

Revance Therapeutics (RVNC) reported strong Q1 2022 results, with total revenue soaring 89.9% to $25.3 million. This surge was driven by the RHA® Collection, generating $20.8 million, up 78.9% year-over-year. The company also secured a $300 million note purchase agreement, enhancing its financial prospects, while total operating expenses amounted to $87.5 million, resulting in a net loss of $64.3 million. A critical PDUFA date for DaxibotulinumtoxinA for injection has been set for September 8, 2022.

Revance Therapeutics (NASDAQ: RVNC) announced it will release its first-quarter financial results on May 10, 2022, after market close. A conference call to discuss these results and provide a business update is scheduled for 1:30 p.m. PT the same day. Revance focuses on innovative aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection, which is under U.S. regulatory review for glabellar lines. The company also holds exclusive U.S. distribution rights for the RHA® Collection of dermal fillers.

Revance Therapeutics, Inc. (NASDAQ: RVNC) announced the FDA's acceptance of its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection, targeting moderate to severe glabellar lines. The BLA has been classified as a Class 2 resubmission, indicating a six-month review period, with a PDUFA goal date of September 8, 2022. The company completed Phase 3 clinical trials for this product and is pursuing U.S. regulatory approval. Additionally, Revance continues to develop a biosimilar to BOTOX® in collaboration with Viatris.

Revance Therapeutics announced presentations at the 2022 American Academy of Neurology Annual Meeting, showcasing data on DaxibotulinumtoxinA for Injection. The oral presentation will cover the ASPEN-1 Phase 3 trial results, demonstrating significant efficacy and safety in treating cervical dystonia. The study revealed two effective doses compared to placebo, with positive long-term safety results from the ASPEN Open Label Study (OLS). This positions DaxibotulinumtoxinA as a promising treatment, bolstering Revance's innovative product line.

Revance Therapeutics (NASDAQ: RVNC) announced a $300 million note purchase agreement with Athyrium Capital Management, enhancing its financial position ahead of the FDA approval for DaxibotulinumtoxinA for Injection. The agreement includes $200 million in committed borrowings and an additional $100 million option. The first tranche of $100 million has been issued, extending the company's cash runway into 2024, contingent on FDA approval. The total notes have a fixed interest rate of 8.5% and mature in 2026 or 2028 under specific conditions.

Revance Therapeutics has resubmitted its Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection to the FDA, targeting treatment for moderate to severe glabellar lines. This resubmission addresses the Complete Response Letter issued in October 2021, following a Type A meeting in December 2021. The process includes the qualification of a new working cell bank to meet FDA requirements.

Revance aims to secure approval after completing multiple drug substance lots and is pursuing broader applications for DaxibotulinumtoxinA in conditions like cervical dystonia and upper limb spasticity.